BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28204639)

  • 1. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
    Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
    Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
    Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
    Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
    Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.
    Field KM; Fitt G; Rosenthal MA; Simes J; Nowak AK; Barnes EH; Sawkins K; Goh C; Moffat BA; Salinas S; Cher L; Wheeler H; Hovey EJ; Phal PM;
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e359-e365. PubMed ID: 29114999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
    Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
    Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.